Antiphospholipid antibodies and neurological manifestations in acute COVID-19: a single-centre cross-sectional study [Текст] / L. A. Benjamina [et al.] // Міжнародний неврологічний журнал. - 2021. - Т. 17, № 5. - С. 105-116. - Бібліогр. в кінці ст. MeSH-головна: КОРОНАВИРУСНЫЕ ИНФЕКЦИИ -- CORONAVIRUS INFECTIONS (патофизиология) НЕВРОЛОГИЧЕСКИЕ СИМПТОМЫ ПРИ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЯХ -- NEUROLOGIC MANIFESTATIONS АНТИТЕЛА АНТИФОСФОЛИПИДНЫЕ -- ANTIBODIES, ANTIPHOSPHOLIPID (анализ) ПЕРЕКРЕСТНЫЕ ИССЛЕДОВАНИЯ -- CROSS-OVER STUDIES Анотація: A high prevalence of antiphospholipid antibodies has been reported in case series of patients with neurological manifestations and COVID-19; however, the pathogenicity of antiphospholipid antibodies in COVID-19 neurology remains unclear. Methods. This single-centre cross-sectional study included 106 adult patients: 30 hospitalised COVID-neurological cases, 47 non-neurological COVID-hospitalised controls, and 29 COVID-non-hospitalised controls, recruited between March and July 2020. We evaluated nine antiphospholipid antibodies: anticardiolipin antibodies [aCL] IgA, IgM, IgG; anti-beta-2 glycoprotein-1 [aβ2 GPI] IgA, IgM, IgG; anti-phosphatidylserine/prothrombin [aPS/PT] IgM, IgG; and anti-domain I β2 GPI (aD1β2 GPI) IgG. Findings. There was a high prevalence of antiphospholipid antibodies in the COVID-neurological (73.3 %) and non-neurological COVID-hospitalised controls (76.6 %) in contrast to the COVID-non-hospitalised controls (48.2 %). aPS/PT IgG titres were significantly higher in the COVID-neurological group compared to both control groups (p 0.001). Moderate-high titre of aPS/PT IgG was found in 2 out of 3 (67 %) patients with acute disseminated encephalomyelitis [ADEM]. aPS/PT IgG titres negatively correlated with oxygen requirement (FiO 2 R Дод.точки доступу: Benjamina, L. A. Patersona, R. W. Mollg, R. Pericleousi, Ch. Browna, R. Mehtaa, P. R. Athaudaa, D. Ziffa, O. J. Heaneyl, J. Checkleyn, A. M. Вільних прим. немає